Abstract: We report two cases of rituximab (RTX)-induced interstitial pneumonia in two lymphoma patients receiving RTX
treatment. Interstitial pneumonia was successfully managed in these two cases after a one-week-long intervention with
corresponding treatments without affecting further treatment of the primary disease. RTX-induced interstitial pneumonia is
characterized by a latent onset with an unclear pathological mechanism and absence of typical symptoms. High-resolution CT
scan can provide valuable evidence for early diagnosis of RTX-induced interstitial pneumonia, which might be attributed
partially to an increased susceptibility to P. jirovecii and fungal infection due to prolonged RTX treatment.